SCOTTSDALE, AZ -- (MARKET WIRE) -- February 08, 2007 -- Medistem Laboratories, Inc. (OTCBB: MDSM) (FRANKFURT: S2U) announced that it is collaborating with the Indiana Center for Vascular Biology and Medicine to perform pre-clinical research on Medistem's proprietary platform AngioStem™. The trials, if successful, will initially position the platform as a potential treatment for critical limb ischemia. The initiation of the pre-clinical phase of experimentation marks a major step for Medistem Laboratories as the company begins taking the necessary steps to commence FDA trials in the U.S.
